Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Form 8.5 (EPT/RI)

29 May 2018 16:38

RNS Number : 5841P
Canaccord Genuity Limited
29 May 2018
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Canaccord Genuity Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vernalis Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Connected party to the Offeree

 

(d) Date dealing undertaken:

25 May 2018

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

No

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

Ord 1p

 

 

Buy

200

 

7p

 

 

7p

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

 

Date of disclosure:

29 May 2018

Contact name:

Sam Cooke

Telephone number:

020 7523 4658

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFMGZKKLVGRZM
Date   Source Headline
18th Mar 20161:06 pmRNSHolding(s) in Company
17th Mar 20167:00 amRNSUnaudited interim results for 6 months to 31/12/15
4th Feb 20163:34 pmRNSNotice of Results for Six Months Ended 31/12/2015
19th Jan 20162:36 pmRNSHolding(s) in Company
6th Jan 20167:00 amRNSVernalis Announces Adenosine Antagonist Licensee
31st Dec 20157:00 amRNSTotal Voting Rights
21st Dec 20157:00 amRNSVernalis Announce CCP-07 Single-Dose Study Results
3rd Dec 20155:19 pmRNSLaunch of 2015 Sharesave Plan
2nd Dec 201511:19 amRNSVernalis Results of Annual General Meeting
2nd Dec 20157:00 amRNSAGM Statement
1st Dec 20154:54 pmRNSHolding(s) in Company
23rd Nov 20155:23 pmRNSHolding(s) in Company
4th Nov 20154:34 pmRNSHolding(s) in Company
30th Oct 20157:00 amRNSTotal Voting Rights
28th Oct 20159:00 amRNSNotice of Annual Report and AGM
15th Oct 20153:54 pmRNSDirector Dealing
15th Oct 20152:02 pmRNSHolding(s) in Company
12th Oct 20157:00 amRNSCCP-08 starts 12 month stability testing
8th Oct 20152:19 pmRNSDirector Dealing
2nd Oct 20157:00 amRNSVernalis plc acquires US rights to MOXATAG®
29th Sep 20157:02 amRNSResults announcement for 18 months ended 30/06/15
25th Sep 201511:09 amRNSBlocklisting Interim Review
16th Sep 20155:08 pmRNSHolding(s) in Company
11th Sep 20157:00 amRNSNotice of Results
8th Sep 20157:00 amRNSVernalis plc Launches Tuzistra(TM) XR
20th Aug 20157:00 amRNSVernalis completes investment in NCE development
18th Aug 20157:00 amRNSAppointment of Non-Executive Director
30th Jun 20151:27 pmRNSAppointment of Non-Executive Director
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20154:34 pmRNSHolding(s) in Company
11th Jun 20157:00 amRNSCCP-07 starts 12 month stability testing
6th May 20151:45 pmRNSBlock Listing Six Monthly Review
6th May 201512:30 pmRNSDirector/PDMR Shareholding
1st May 20154:38 pmRNSHolding(s) in Company
1st May 20157:00 amRNSFDA approves NDA for Tuzistra XR
30th Apr 20153:27 pmRNSHolding(s) in Company
23rd Apr 20152:39 pmRNSHolding(s) in Company
7th Apr 20157:00 amRNSVernalis enters into research collaboration
31st Mar 201512:47 pmRNSTotal Voting Rights
6th Mar 20157:00 amRNSVernalis and AKP Achieve Research Milestone
26th Feb 20157:00 amRNSVernalis licenses proprietary ARA technology
18th Feb 201512:51 pmRNSHolding(s) in Company
10th Feb 20157:00 amRNSUnaudited interim results for periods to 31/12/14
5th Feb 20155:53 pmRNSHolding(s) in Company
30th Jan 201511:50 amRNSNotice of Interim Results Period Ended 31 Dec 2014
26th Jan 20151:06 pmRNSHolding(s) in Company
21st Jan 201511:00 amRNSChange of Non-Executive Director
31st Dec 20147:00 amRNSTotal Voting Rights
19th Dec 20147:00 amRNSUpdate on AUY922 development programme
28th Nov 20147:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.